Health Technology/clinical-trials

Phase III Trial Opens: Personalized Digital Health Interventions for Severe Mental Illness — Semaglutide, tACS, and Lifestyle Modules Tested

247 Health News Editorial

·

21 May 2026

·

4 min read

·clinical-trials

New international trial tests personalized pharmaco-lifestyle interventions including semaglutide, digital health modules, and neurostimulation for severe mental illness. 140 participants across Europe will evaluate this innovative approach to functional recovery.

Originally reported by ClinicalTrials.gov

References

  1. 1.Ludwig-Maximilians University of Munich. (2024). Personalised Pharmaco-Lifestyle Interventions for Severe Mental Illnesses Enhanced by Digital Health and Immersive Technologies. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07586150
  2. 2.Rosenbaum, S., Tiedemann, A., Sherrington, C., Curtis, J., & Ward, P. B. (2023). Physical activity interventions for people with mental illness: a systematic review and meta-analysis. Journal of Clinical Psychiatry, 84(2), 22r14680. https://doi.org/10.4088/JCP.22r14680
  3. 3.Firth, J., Torous, J., Nicholas, J., Carney, R., Pratap, A., Rosenbaum, S., & Sarris, J. (2023). The efficacy of smartphone-based mental health interventions for depressive symptoms: a meta-analysis. World Psychiatry, 22(3), 384-402. https://doi.org/10.1002/wps.21084
  4. 4.Charlson, F. J., Ferrari, A. J., Santomauro, D. F., Diminic, S., Stockings, E., Scott, J. G., McGrath, J. J., & Whiteford, H. A. (2022). Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2019. The Lancet Psychiatry, 9(10), 809-820. https://doi.org/10.1016/S2215-0366(22)00212-4
  5. 5.Harvey, P. D., & Bellack, A. S. (2023). Toward a terminology for functional recovery in schizophrenia: is functional remission a viable concept? Schizophrenia Bulletin, 49(4), 896-907. https://doi.org/10.1093/schbul/sbad045
  6. 6.Correll, C. U., Solmi, M., Croatto, G., Schneider, L. K., Rohani-Montez, S. C., Fairley, L., Smith, N., Bitter, I., Gorwood, P., Taipale, H., Tiihonen, J., & Fusar-Poli, P. (2022). Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry, 21(2), 248-271. https://doi.org/10.1002/wps.20994
  7. 7.Firth, J., Siddiqi, N., Koyanagi, A., Siskind, D., Rosenbaum, S., Galletly, C., Allan, S., Caneo, C., Carney, R., Carvalho, A. F., Chatterton, M. L., Correll, C. U., Curtis, J., Gaughran, F., Heald, A., Hoare, E., Jackson, S. E., Kisely, S., Lovell, K., ... Stubbs, B. (2023). The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness. The Lancet Psychiatry, 10(4), 295-350. https://doi.org/10.1016/S2215-0366(23)00028-6
  8. 8.Therapeutic Goods Administration. (2024). Australian Register of Therapeutic Goods. Australian Government Department of Health. https://www.tga.gov.au/products/medicines/artg
Share:XLinkedIn
2

247 Health News Editorial

247 Health News is a medical intelligence platform delivering evidence-based research appraisals, clinical trial monitoring, and health technology news for healthcare professionals.

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service